- The Company expects to exceed 2022 full-year guidance for net product revenues
- Preliminary net product revenues for the fourth quarter and full-year 2022 are expected to total $235.5
On January 9, 2023, Apellis Pharmaceuticals, Inc. (the “Company”) posted on its website a corporate presentation, which it plans to present at the 41st Annual J.P. Morgan Health Care Conference on
On January 9, 2023 during its scheduled presentation at the 41st Annual J.P. Morgan Healthcare Conference, Bruker Corporation (the “Company”) stated that its current preliminary expectation for revenue for
2022 Net cash provided by operating activities (GAAP) expected to be approximately $2,140 million to $2,150 million; 2022 Adjusted Cash Receipts(1) (non-GAAP) expected to be
Announcing addition of two new TCRs to the library, estimated to double the addressable market; plans to further expand TCR library using hunTR® TCR discovery platform
Increasing patient enrollment to